Mouse Anti-HTATIP2 Recombinant Antibody (3E11) (CBMAB-A4148-LY)

Cardinale, C. J., Chang, X., Wei, Z., Qu, H. Q., Bradfield, J. P., Polychronakos, C., & Hakonarson, H. (2023). Genome-wide association study of the age of onset of type 1 diabetes reveals HTATIP2 as a novel T cell regulator. Frontiers in Immunology, 14, 1101488.

Nguyen, T. T., Rajakannu, P., Pham, M. D. T., Weman, L., Jucht, A., Buri, M. C., ... & Hegi, M. E. (2023). Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA‐repair protein N‐methylpurine DNA glycosylase (MPG). Molecular Oncology.

Hegi, M., Nguyen, T. T., Rajakannu, P., Pham, M. D. T., Weman, L., Jucht, A., ... & Van Dommelen, K. (2022). Epigenetic silencing of HTATIP2 in glioblastoma enhances nuclear translocation of the DNA-repair protein MPG affecting treatment resistance.

Zhang, X., Zhang, X., Li, X., Bao, H., Li, G., Li, N., ... & Dou, J. (2020). HTATIP2 Represents an Innovative Bio-marker in Hepatocellular Carcinoma Detection.

Zhao, B., Chen, Y., Hu, S., Yang, N., Liu, M., Li, J., ... & Wu, X. (2020). Characterization of HTATIP2 and its role during hair follicle cycles in Angora rabbit. Genome, 63(3), 179-187.

Li, M., Li, J., Guo, X., Pan, H., & Zhou, Q. (2020). Absence of HTATIP2 expression in A549 lung adenocarcinoma cells promotes tumor plasticity in response to hypoxic stress. Cancers, 12(6), 1538.

Zhang, P., Chen, Z., Chen, L., Zang, H., Zhu, B., Shao, W., & Niu, W. (2020). Clinical significance of changes in AFP, HTATIP2/TIP30, B7-H4 and inflammatory cytokines after transcatheter arterial chemoembolization. Journal of BUON, 25(2), 1206-1211.

Zheng, Z. J., Fu, J., Zhi, F., Liu, W. J., Guo, Y. J., Zhu, D. D., & Mo, J. G. (2018). The effects of interventional therapy on serum HTATIP2/TIP30, B7-H4 and short-term curative effect in primary hepatocellular carcinoma. Eur Rev Med Pharmacol Sci, 22(20), 6778-83.

Nanok, C., Jearanaikoon, P., Proungvitaya, S., & Limpaiboon, T. (2018). Aberrant methylation of HTATIP2 and UCHL1 as a predictive biomarker for cholangiocarcinoma. Molecular Medicine Reports, 17(3), 4145-4153.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols